Latest & greatest articles for ranitidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ranitidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ranitidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ranitidine

1. [OMEPRAZOL VS RANITIDINE IN UPPER DIGESTIVE BLEEDING] (PubMed)

[OMEPRAZOL VS RANITIDINE IN UPPER DIGESTIVE BLEEDING] Pectic ulcer is the most frequent cause of gastrointestinal bleeding. The homeostatic mechanism of bleeding, and coagulation, does not happen with values of pH less than 5,0. Therefore neutralization of gastric acidity (pH more than 5,0) is a recourse of control, improve the evolution and healing of peptic ulcer and to avoid a new bleeding. The aim of this study was to compare the results of treatment with omeprazole and ranitidine, in 57 (...) patients admitted at emergency room of the Hospital Central de la Polic a Nacional del Per with endoscopic diagnosis of peptic ulcer, using Forrest classification. Patients received omeprazole 40 mg in bolus IV, followed by continuos infusion of 8 mg/hour for 72 hours (group A) or ranitidine 50 mg IV each 8 hours for 72 hours (group B). A new endoscopy was made 72 hours after admission demostrated a succesful therapy in both group. Bleeding stopped in 26/27 patients in group A (96,2%) and in 23/30

2019 Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru Controlled trial quality: uncertain

2. Ranitidine

Ranitidine Top results for ranitidine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ranitidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

4. Ranitidine

Ranitidine USE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCY 0344 892 0909 USE OF H2 RECEPTOR ANTAGONISTS IN PREGNANCY (Date of issue: January 2015 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Histamine H2 (H 2 ) receptor antagonists (...) (cimetidine, famotidine, nizatidine and ranitidine) reduce gastric acid output and thus gastric acidity. H 2 receptor antagonists are used in the symptomatic relief of chronic episodic dyspepsia and gastro-oesophageal reflux disease, in the prevention and treatment of gastric or duodenal ulceration, and prior to general anaesthesia in patients at risk of acid aspiration. The BNF suggests ranitidine as the preferred H 2 receptor antagonist for use in pregnancy after lifestyle modification, and antacid

2014 UK Teratology Information Service

5. Cohort study: Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants

Cohort study: Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants Article Text Aetiology Cohort study Ranitidine use is associated with increased

2013 Evidence-Based Medicine (Requires free registration)

6. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials

The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

7. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole (PubMed)

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole BACKGROUND: The use of non-steroidal anti-inflammatory drugs (NSAID) is associated with an increased risk of gastric ulcer (GU) development. METHODS: This multicentre, randomized, double-blind, parallel-group trial compared endoscopic healing rates at 4 and 8 weeks after treatment with oral esomeprazole 40 or 20 mg once daily, or ranitidine (...) 150 mg twice daily, in patients with 1 baseline GU > or = 5 mm but no GUs or duodenal ulcers >25 mm in diameter who received continued cyclooxygenase-2-selective or non-selective NSAID therapies. The primary outcome was the percentage of patients in each treatment group who had no GUs at week 8. RESULTS: Four hundred and forty patients were randomized to treatment. At week 8, GU healing rates (95% CI) with esomeprazole 40 mg, esomeprazole 20 mg and ranitidine were 85.7 (79.8-91.7)%, 84.8

Full Text available with Trip Pro

2007 EvidenceUpdates Controlled trial quality: predicted high

8. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? (PubMed)

Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of serious gastroduodenal events. To minimise these risks, patients often require concomitant acid-suppressive therapy. We conducted a literature review of clinical trials examining use of ranitidine 150 mg twice daily to heal gastroduodenal ulcers (GU) in NSAID recipients. Seven studies were (...) identified. After 8 weeks' treatment with ranitidine, GU healing rates ranged from 50% to 74% and rates of duodenal ulcer (DU) healing ranged from 81% to 84%. Ranitidine was more effective when NSAIDs were discontinued (healing rates reaching 95% and 100%, respectively). The ulcer healing rate with sucralfate was similar to that of ranitidine. However, proton pump inhibitor (PPI) therapy was associated with significantly greater rates of both GU and DU healing than ranitidine; 8-week GU rates were 92

Full Text available with Trip Pro

2006 EvidenceUpdates

9. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

10. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra

Six-month management of patients following treatment for gastroesophageal reflux disease symptoms: a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical pra Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

11. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole A systematic comparison of triple therapies for treatment of Helicobacter pylori (...) infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole Janssen M J, Van Oijen A H, Verbeek A L, Jansen J B, De Boer W A Authors' objectives To evaluate whether there is a difference in the efficacy between triple therapies with proton-pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus clarithromycin and either amoxicillin or a nitroimidazole, for the treatment of Helicobacter pylori (H. pylori) infection. Searching

2001 DARE.

12. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

2001 DARE.

13. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. (PubMed)

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients and to assess if these treatments affect the risk of nosocomial pneumonia.Published studies retrieved through Medline and other databases. Five meta-analyses evaluated effectiveness in terms of bleeding rates (A: ranitidine (...) v placebo; B: sucralfate v placebo) and infectious complications in terms of incidence of nosocomial pneumonia (C: ranitidine v placebo; D: sucralfate v placebo; E: ranitidine v sucralfate). Trial quality was determined with an empirical ad hoc procedure.Rates of clinically important gastrointestinal bleeding and nosocomial pneumonia (compared between the two study arms and expressed with odds ratios specific for individual studies and meta-analytic summary odds ratios).Meta-analysis A (five

Full Text available with Trip Pro

2000 BMJ

14. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials Messori A, Trippoli (...) S, Vaiani M, Gorini M, Corrado A Authors' objectives To determine the effectiveness of ranitidine and sucralfate in the prevention of stress ulcer in critical patients, and to assess if these treatments affect the risk of nosocomial pneumonia. Searching The authors searched MEDLINE from 1966 to June 2000 using the keywords 'stress', 'pneumonia', 'ranitidine' and 'sucralfate'. Randomised studies were identified using the keywords 'randomized controlled trial' or 'random'. The search

2000 DARE.

15. Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy

Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Gisbert J P, Gonzalez L, Calvet X, Roque M (...) , Gabriel R, Pajares J M Authors' objectives To compare the efficacy of proton-pump inhibitors (PPI) versus ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori (H. pylori) eradication. Searching Searches were performed in the PubMed database up to October 1999. The search strategies are reported in the paper. A manual search of abstracts from 1995 to 1999 was also undertaken from the following congresses: International Workshop on Gastroduodenal Pathology

2000 DARE.

16. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis

Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis Ofman J J, Yamashita B D, Siddique R M, Larson L R, Willian M K Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rabeprazole (RAB), 20 mg/day for 8 weeks, and ranitidine (RAN), 150 mg 4 times daily for 8 weeks, as initial and maintenance therapy in patients with erosive oesophagitis. Type of intervention Treatment. Economic study type Cost-effectiveness

2000 NHS Economic Evaluation Database.

17. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Kaplan-Machlis B, Spiegler G E, Zodet (...) M W, Revicki D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study considered omeprazole sodium (20 mg once daily) and ranitidine hydrochloride (150 mg twice daily) for the treatment of symptomatic gastroesophageal

2000 NHS Economic Evaluation Database.

18. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies van Oijen A H, Verbeek A L, Jansen J B, de Boer W A Authors' objectives (...) To compare treatment of Helicobacter pylori infection with ranitidine bismuth citrate- and proton pump inhibitor-based triple therapies. Searching The authors searched MEDLINE and Current Contents, and manually reviewed abstracts submitted to meetings of the American Gastroenterological Association (Digestive Disease and the United European Gastroenterology weeks) and the European Helicobacter Study Group, for the period 1996 to 1999. Study selection Study designs of evaluations included in the review

2000 DARE.

19. Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy

Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Mason I (...) , Marchant N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Management of acid-related dyspepsia in general practice using either omeprazole or antacid-alginate/ranitidine. Type of intervention Treatment. Economic study type Cost

1999 NHS Economic Evaluation Database.

20. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease

Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Stalhammar N, Carlsson J, Peacock R, Muller-Lissner S, Bigard M, Porro G B, Ponce J, Hosie J, Scott M, Weir D G, Fulton C, Gillon (...) K, Bardhan K D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of omeprazole (10 or 20 mg once daily) or ranitidine (150 mg twice daily) as initial therapy, and subsequent open maintenance treatment, following initial

1999 NHS Economic Evaluation Database.